In order to combat CD19, Romanski et al. employed CAR to transduce human malignant non-Hodgkin’s lymphoma patients’ natural killer cells, NK-92, and they were able to show that CAR-NK-92 can preferentially lyse B cells that express CD19 [43]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.